• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE-TEX® VASCULAR GRAFT; PROSTHESIS, VASCULAR GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE-TEX® VASCULAR GRAFT; PROSTHESIS, VASCULAR GRAFT Back to Search Results
Model Number RRT08070080L
Device Problem Microbial Contamination of Device (2303)
Patient Problems Purulent Discharge (1812); Hematoma (1884); Sepsis (2067); Seroma (2069); No Clinical Signs, Symptoms or Conditions (4582)
Event Date 08/02/2014
Event Type  Injury  
Event Description
Reportedly on (b)(6) 2014, this patient underwent an endovascular treatment for an extensive occlusive peripheral arterial disease in which a gore-tex® vascular graft was implanted proximally on the left axillary artery and distally to the deep femoral artery.According to reports, an adjunctive procedure was performed and a gore-tex® stretch vascular graft was implanted proximally on the gore-tex® vascular graft and distally to the left supra-articular popliteal artery.Reportedly, the whole procedure was uneventful, no adverse events or complications were recorded and the patency of the devices were confirmed at the end of the procedure.The patient received an additional antiplatelet medication during the procedure and the devices were implanted and retained.According to reports, on (b)(6) 2014 series of adverse events were recorded and this includes the following: "infection of the left axillofemoral prosthesis", a reintervention was performed and the devices were explanted on (b)(6) 2014.Another adverse event alert was recorded on the same date as " severe sepsis with cutaneous origin, left lower limb (bypass scar)" and a reintervention was performed."fluid infiltration around the left axillofemoral bypass" and washing and drainage of the fluid through the surgical site of the left axillofemoral-popliteal bypass were performed on (b)(6) 2014 respectively.On (b)(6) 2014, another adverse event termed " hematoma in the proximal part of the left axillary-subclavian bypass" was discovered which necessitated a reintervention.A surgical evacuation of the hematoma was performed, this procedure also involved explantation of the prosthesis and insertion of an aorto-bi-femoral bypass and a left femoro-popliteal bypass.Reportedly on (b)(6) 2014, the patient was pronounced dead.However the physician confirmed that the death of the patient is not related to the gore devices used in this procedure.The cause of death was indicated to be colonic ischemia and multivisceral failure syndrome.2200-a:-other was used to capture hematoma.
 
Manufacturer Narrative
H3 and h6 code b20: the device remains implanted in the patient.Therefore a device evaluation could not be performed.H6 code b14: a review of manufacturing records verified that the lot involved in this complaint met all pre-release specifications.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Event Description
Reportedly on (b)(6) 2014, this patient underwent an endovascular treatment for an extensive occlusive peripheral arterial disease in which a gore-tex® vascular graft was implanted proximally on the left axillary artery and distally to the deep femoral artery.According to reports, an adjunctive procedure was performed and a gore-tex® stretch vascular graft was implanted proximally on the gore-tex® vascular graft and distally to the left supra-articular popliteal artery.Reportedly, the whole procedure was uneventful, no adverse events or complications were recorded and the patency of the devices were confirmed at the end of the procedure.The patient received an additional antiplatelet medication during the procedure and the devices were implanted and retained.On (b)(6) 2014, an adverse events termed"fluid infiltration around the left axillofemoral bypass" was recorded.Washing and drainage of the fluid through the surgical site of the left axillofemoral-popliteal bypass were performed on (b)(6) 2014, and (b)(6) 2014, respectively.On the same day another adverse event termed "severe sepsis with cutaneous origin, left lower limb (bypass scar)" was recorded.Purulent flow from the left lower limb bypass scar was found.It is indicated that this event is related to the initial procedure.A reintervention was performed.On the same day another adverse event termed "infection of the left axillofemoral prosthesis" was recorded.It is indicated that this event is related to the initial procedure.On (b)(6) 2014, the device was explanted because of the infection.Reportedly on (b)(6) 2014, the patient was pronounced dead.However the physician confirmed that the death of the patient is not related to the gore devices used in this procedure.The cause of death was indicated to be colonic ischemia and multivisceral failure syndrome.
 
Manufacturer Narrative
Cause investigation and conclusion: a review of the manufacturing records, including sterilization records, indicated the lots met all pre-release specifications.Neither images enabling direct assessment of product performance nor the product itself, which was discarded to the facility, were returned for evaluation.Based on the incident description and the subsequent investigation, no further information was provided to gore, therefore we are unable to determine the cause of this incident and assign a root cause.No potential new or different reasonably foreseeable risks related to the device or its use were identified based on this event.Ongoing risk/benefit assessment affirms risk acceptability based on current performance.No corrective measures are needed as a result of this event.Gore will continue to monitor post-market data closely to ensure that the risk assessment remains accurate.It was reported in the study database that fluid infiltration and infection were related to the initial procedure.No further information was provided.The cause of the infection could not be establish based on available information.In the instructions for use the following is stated: possible complications with the use of any vascular prosthesis complications which may occur in conjunction with the use of any vascular prosthesis include but are not limited to: infection; ultrafiltration or perigraft seroma; or perigraft hematomas.
 
Manufacturer Narrative
Add e0307 - seroma as additional health effect - clinical code.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE-TEX® VASCULAR GRAFT
Type of Device
PROSTHESIS, VASCULAR GRAFT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL WEST B/P
1505 n. fourth street
flagstaff AZ 86004
Manufacturer Contact
wilson okeke
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key17258196
MDR Text Key318450645
Report Number2017233-2023-04086
Device Sequence Number1
Product Code DSY
Combination Product (y/n)N
Reporter Country CodeFR
PMA/PMN Number
K802095
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional
Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date 11/22/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/05/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date03/12/2019
Device Model NumberRRT08070080L
Device Catalogue NumberRRT08070080L
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received06/07/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured03/13/2014
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age61 YR
Patient SexMale
-
-